Literature DB >> 12050866

Health care industries' perspective of viral load assays: the VERSANT HIV-1 RNA 3.0 assay.

Tarek Elbeik1, Richard A Loftus, Scott Beringer.   

Abstract

This article will compare the VERSANT HIV-1 RNA 3.0 (bDNA 3.0) assay with other HIV-1 viral load assays, particularly the AMPLICOR HIV-1 MONITOR (Amplicor 1.5), the industry standard. The discussion will cover the history of viral load assay development and challenges to the field. It will finish with a description of the evolving markets for viral load assays in the developing world and the impact of variations in the different assays on their ability to reach those markets and patient populations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050866     DOI: 10.1586/14737159.2.3.275

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  2 in total

1.  Simultaneous runs of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the system 340 platform provide reliable quantitation and improved work flow.

Authors:  Tarek Elbeik; Norman Markowitz; Patricia Nassos; Uday Kumar; Scott Beringer; Barbara Haller; Valerie Ng
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

2.  Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA).

Authors:  Tarek Elbeik; Johan Surtihadi; Mark Destree; Jed Gorlin; Mark Holodniy; Saeed A Jortani; Ken Kuramoto; Valerie Ng; Roland Valdes; Alexandra Valsamakis; Norah A Terrault
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.